Transforming growth factor β as a therapeutic target in systemic sclerosis
Authors:
- 1 April 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 5 (4) , 200-206
Abstract
In patients with systemic sclerosis, impaired activity of transforming growth factor β (TGF-β) has a central role in the pathogenesis of fibrosis, which leads to the progression of the disease and severe organ damage. In this context, the authors discuss the mechanisms of aberrant TGF-β signaling and highlight the potential of TGF-β as a therapeutic target in systemic sclerosis. Transforming growth factor β (TGF-β) is a pleiotropic cytokine with vital homeostatic functions. Aberrant TGF-β expression is implicated in the pathogenesis of fibrosis in systemic sclerosis (SSc); thus, TGF-β represents a molecular therapeutic target in this disease. Anti-TGF-β monoclonal antibody has been evaluated in a small trial of early SSc, with disappointing results. Antibodies against the αvβ6 integrin that prevent latent TGF-β activation, however, have shown promise in preclinical studies. Small-molecule inhibitors of TGF-β-receptor activity are effective in animal models of fibrosis. Imatinib mesylate and related tyrosine kinase inhibitors also block TGF-β pathways and abrogate fibrotic responses. The blocking of TGF-β activity might lead to spontaneous immune activation, epithelial hyperplasia and impaired wound healing. Loss of immune tolerance is a potential concern in an autoimmune disease such as SSc. Novel insights from microarray-based gene expression analyses and studies of genetic polymorphisms in TGF-β signaling could aid in identifying patients who are most likely to respond to anti-TGF-β treatment. This intervention promises to have a major impact on the treatment of SSc. Concerns regarding efficacy and safety and whether biomarkers can indicate these features, questions regarding appropriate dosing and timing of therapy, and identification of potential responders are critical challenges ahead.Keywords
This publication has 92 references indexed in Scilit:
- Molecular framework for response to imatinib mesylate in systemic sclerosisArthritis & Rheumatism, 2009
- Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosisArthritis & Rheumatism, 2008
- Molecular ablation of transforming growth factor β signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosisArthritis & Rheumatism, 2008
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Targeting transforming growth factor-β signalingCurrent Opinion in Oncology, 2007
- TGF‐β signaling: A tale of two responsesJournal of Cellular Biochemistry, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Inhibition of Transforming Growth Factor-β1–induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARAMolecular Biology of the Cell, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003